Comparative analysis shows better survival from neoadjuvant immunochemotherapy in esophageal cancer, suggesting survival focus is crucial.
Recurrence patterns differ between the two modalities in post-treatment pathological stage I patients, with neoadjuvant chemotherapy plus immunotherapy associated with better survival. Studies comparing the two should focus more on survival than tumour response in oesophageal squamous cell cancer.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: